*this represents the p-value comparing the CardioCEAL-STARflex device to both, the Amplatzer and the Helex device. There was no significant difference between the Amplatzer and Helex device. # this represents the p-value comparing the Helex device to both, the Amplatzer and the CardioSEAL-STARflex device. There was no significant difference between the Amplatzer and CardioSEAL-STARflex device.
Conclusions:
The periprocedural and long-term neurological event rates are low regardless of the device used. The recurrent neurological event rate was significantly higher after CardioSEAL-STARflex than after Amplatzer or Helex implantation. This has important implications regarding the interpretation of trials comparing PFO closure to medical management. Background: Percutaneous pulmonary valve implantation (PPVI) is a non-surgical transcatheter treatment for right ventricular to pulmonary artery conduit dysfunction. One of the rare but significant risks of this procedure is acute coronary occlusion following valve deployment. Proximity of coronary arteries has previously been assessed using time-consuming and costly ECG gated contrast CT scanning or MRI. We assessed the utility of non-ECG gated contrast CT scanning as an alternative for assessing the coronary position in patients planned to undergo PPVI. Methods: We studied a series of 22 consecutive patients presenting to our institution for PPVI. The underlying diagnoses of these patients varied. In all of the patients, we used the rapid, highly-accessible and relatively cheap technique of non-ECG gated 32-slice contrast CT to assess the relationship of the coronary arteries to the proposed site of PPVI in 3 planes -axial, saggital and coronal. Patients were only subsequently selected for PPVI if there was a distance of at least 3 mm between the main coronary vessels and region of proposed valve deployment. Results: The mean age of patients selected for PPVI was 26. Non-ECG gated contrast CT scanning was found to be highly effective in detecting the position of the coronary arteries, allowing coronary identification in the axial plane 93% of the time, saggital plane 87% of the time and in the coronal plane 87% of the time. No patient experienced acute coronary occlusion when the exclusion criteria of Ͻ3 mm between proposed valve deployment site and nearest distance of coronary artery was employed. Conclusions: Non-ECG gated contrast CT is effective, rapid and cost-effective in allowing coronary characterisation before PPVI. A distance of 3 mm between coronary artery and valve implantation site seems to be a safe distance to avoid PPVI related coronary occlusion. More studies are required to assess this in further detail. Background: Transcatheter closure of peri-membranous ventricular septal defects (pmVSDs) has been associated with a significant risk of complete heart block, leading most groups to abandon the technique. Our objective was to describe the initial world experience of pmVSD closure with a newly designed occluder. Methods: Patients with pmVSD underwent catheter closure using the Amplatzer® Membranous VSD Occluder 2 (AGA -St Jude, Minneapolis, MN, USA). Results: Nineteen patients from the 4 centers initially involved worldwide were prospectively included and followed for at least 30 days (median 48, range 31 -245 days). Patients ranged in age from 1.4 to 62 years (median 6 years) and in weight from 9.3 to 96 kg (median 26 kg). The Qp/Qs ratio was (mean Ϯ SD) 1.9 Ϯ 1.6. The size of the defect on left ventricular side was 9.9 Ϯ 3.5 mm (range 4.6 -16 mm) and the orifice on right ventricular side was 8.1 Ϯ 2.8 mm (range 3.9 -14 mm) by echocardiography. Mean device size was 9.4 Ϯ 2.4 mm (range 5 -14 mm). An eccentric device was used in 9 patients (47%) and a concentric device in 10 (53%). A device was successfully implanted in 18 patients (95%). Procedural time was 122 Ϯ 39 min (range 60 -207 min). There were no significant procedural complications. Mild (0-2 mm) residual shunt was initially observed in 14 patients (78%). At last follow-up, mild residual shunt was still observed in only 3 patients (17%). There was no significant increase of aortic or tricuspid regurgitation. No patient showed any degree of AV block, although one patient developed a left anterior fascicular block. Holter evaluation was obtained in 13/18 patients, and was normal in all. Conclusions: Transcatheter closure of pmVSD with the Amplatzer® pmVSD Occluder 2 is safe and effective. No conduction abnormalities or any other complications were observed on short-term follow of this initial human series. Background: In this report we present 10 year experience with 78 patients (pts) with perimembranous ventricular septal defects (PMVSDs) who underwent transcatheter closure at 5 different Institutions with the Amplatzer asymmetric PMVSD occluder. Methods: The age of the pts ranged from 0.3 to 15 years. During the study period 35 other patients were excluded from transcatheter closure because they did not fulfil the patient selection criteria (distance less than 2 mm from the PMVSD to the aortic valve, size of VSD in relation to patients age). Results: The devise was permanently implanted in 72/78 patients. Complete occlusion of the communication at six month, one-year, and 2-year follow-up was observed in 93%, 97 %, and 97% patients, respectively. Main complications included: Early. Were observed in patients less than one year (body weight Ͻ 8 Kg) and included: a. Device embolization (2 patients-catheter and surgical removal, respectively), b. severe procedural bradycardia (5 pts) and c. Mobitz II and complete heart block heart in 3 and 1 patients respectively. (sinus rhythm after device removal). Late (follow-up 6 months-10 years). Complete heart block was developed in one patient 4-year old with Down syndrome. No other patient developed heart block during the follow-up. Three patients developed mild aortic regurgitation. In one of them the regurgitation was not seen at the 1-year follow-up. No other complications were observed. Conclusions: Transcatheter closure using the Amplatzer APMVSD occluder is as a safe and effective nonsurgical alternative that should be offered in properly selected patients with PMVSDs. It should be noted, however, that with the current design of the occluder-delivery system the procedure carries an increased risk in small patients less than one-year of age. Finally, due to anatomic reasons, this therapy cannot be offered to significant number of patients with these defects. Cardiox Corporation, Columbus, OH Background: The current "gold standard" for detection and quantification of right-to-left shunts (RLS) is transesophageal echocardiography (TEE). The Flow Detection System (FDS) (Cardiox Corp., Columbus, OH) is a new, minimally invasive, diagnostic test, based on transdermal detection of Indocyanine Green (ICG) dye (Pulsion Medical Systems AG, Munich, Germany). The present study was performed to determine optimum ICG dosing and injection timing protocols, as well as the system's accuracy in the detection of RLS. Methods: Various ICG dosages and injection timing protocols were evaluated in eight (8) patients, with known RLS, to determine the optimal dose and injection timing to facilitate detection of RLS with FDS. 20 additional patients underwent testing with power m-mode transcranial Doppler (TCD) and subsequent FDS. Ten (10) patients with large RLS, (Spencer grades IV or V by TCD) were selected to comprise the study group. Ten (10) additional patients with Spencer grades 0 or I shunt by TCD were selected to comprise a control group. All patients were evaluated just prior to a scheduled catheterization, with both TCD and FDS using the dosing and timing parameters developed in the initial cohort of eight patients. In the study group, results were also compared with RLS assessment by intra-cardiac echocardiography (ICE -Johnson & Johnson, NJ) performed during the catheterization. Results: All ten study subjects with TCD-proven RLS exhibited a Shunt Conductance Index (SCI) Ͼ 0, reflecting the presence of a RLS (sensitivity ϭ 100%). FDS was also in TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM www.jacc.tctabstracts2012.com JACC Vol 60/17/Suppl B | October 22-26, 2012 | TCT Abstracts/POSTER/PFO, ASD, and Congenital Heart Disease B225 agreement with ICE results in all ten. Nine (9) of ten (10) patients with TCD-negative RLS, had SCI ϭ 0.
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Conclusions:
The Cardiox FDS, with the established dosage of ICG dye and timing protocols, provided consistent detection of significant RLS (Spencer Grades IV or V), with a good negative predictive value.
